Clinical trials on Non-small cell lung cancer

Overview of Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC) represents the most prevalent type of lung cancer, accounting for approximately 85% of all lung cancer cases. Unlike its counterpart, small cell lung cancer, NSCLC progresses more slowly and is categorized into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype is identified based on the type of cells found in the cancer and their appearance under a microscope. Adenocarcinoma is the most common form of NSCLC, typically originating in the outer parts of the lung and is most frequently diagnosed in people who have never smoked.

Risk Factors and Symptoms

Several risk factors contribute to the development of NSCLC, including smoking, exposure to secondhand smoke, radon gas, asbestos, and other carcinogens. Family history of lung cancer and previous radiation therapy to the chest also increase the risk. Symptoms of NSCLC may include a persistent cough, coughing up blood, chest pain, shortness of breath, hoarseness, and unexplained weight loss. However, symptoms often do not appear until the cancer is advanced, making early detection challenging.

Treatment Options

Treatment for NSCLC varies depending on the cancer stage, the patient’s overall health, and other factors. Options may include surgery to remove the tumor, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. Recently, advances in immunotherapy have provided new hope for NSCLC patients, offering treatments that help the immune system recognize and fight cancer cells more effectively. The choice of treatment is highly personalized, aiming to achieve the best possible outcome for each patient.